trending Market Intelligence /marketintelligence/en/news-insights/trending/oockcwmkanp19jdzoromiw2 content esgSubNav
In This List

Cellect Biotechnology appoints chief business officer

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Cellect Biotechnology appoints chief business officer

Israel-based Cellect Biotechnology Ltd. named Andrew Sabatier as its chief business officer to head its U.S. center of operations.

Sabatier was most recently leading GE Cell Therapy's sales and market development for U.S. and Canada. Prior to joining GE, he was the sales vice president of Biosafe America Inc., a company acquired by General Electric Co.

Cellect Biotechnology is a biotechnology focused on developing technologies for selecting stem cells from any given tissue to improve a variety of related therapies.